Objectives: This study aimed to investigate the effectiveness of pharmacist intervention in reducing and preventing prescribing errors of investigational drugs for cancer patients. Materials and methods: A retrospective study was conducted during two periods: a baseline period . The investigational drug service (IDS) pharmacists performed active interventions during the intervention period. Results: Among 12,387 investigational drug orders, 395 (6.1%) prescribing errors were detected in 6477 orders at the baseline period, and 278 errors (4.7%) were detected in 5,910 orders at the intervention period. To identify factors that affect prescribing errors, three models were constructed for the multivariate analysis. Among factors affecting prescribing errors, sponsor initiated trial (SIT) was the strongest factor (AOR: 4.16, 95% CI: 3.31-5.23). Pharmacist intervention reduced prescribing errors by at least 25% in all constructed models after adjusting for confounding variables. Prescribing errors were 1.3 times higher when dealing with intravenous medications than when dealing with oral medications. There were 60% fewer prescribing errors in the blinded study than in the open study. SIT and multi-center/multi-nation studies had 4.2 and 2.4 times more frequent prescribing errors than in investigator-initiated trials (IIT) and single-center/ single-nation studies, respectively. Fewer errors occurred in phase 2 and trials covering both phase 1 and phase 2 (phase 1/2) than in phase 3 trials. Conclusions: The IDS pharmacist intervention in cancer clinical trials was associated with significant reductions in prescribing errors and may lead to increased medication safety.
Introduction
In Korea, the number of clinical researches is increasing rapidly year by year, especially clinical studies involving cancer patients. 1 Investigational drugs are often considered to be high-risk or hazardous medications and therefore require consideration for additional safe practices. 2 However, safe practices for ordering, handling, dispensing, and administering investigational drugs have not been standardized. 3 Medication errors do occur in clinical trials. According to the report on medication safety in cancer clinical trials, the processes in which the errors originated were prescribing (47%), administering (10%), dispensing (6%), and monitoring (5%). 4 Prescribing errors are caused by factors such as misuse of common abbreviations and confusion between look-like or sound-like drugs. 5 In addition to these common causes, factors specific to the investigational study setting may contribute to medication ordering errors. These include failure to fill in a study protocol number, an appropriate subject identifier (subject number or randomization number), or a study visit number. These factors can be especially important when an investigational study involves dispensing a drug in a blinded, patient-specific, or visit-specific manner, because they can contribute to violations of the study protocol, and they can potentially place the study subject at unforeseen risk. 6 In addition, in recent years, protocol design has become more complex, and the contents of protocols are being written in detail to reduce bias or misunderstanding due to the unclear expression of the protocol. Therefore, there are more and more items to adhere to. Due to these specificities, investigational drugs differ from commercial drugs in terms of methods and contents for verifying of an order.
Although several articles have described interest in pharmacist intervention to reduce prescribing errors in intensive care and cancer chemotherapy, [7] [8] [9] [10] [11] [12] [13] [14] there are no studies accessing the value of pharmacist intervention in reducing prescribing errors in clinical trials. Considering the fact that clinical trials in the oncology field are more complicated than trials for other medicines, which result in frequent errors in the prescription, it is necessary to study the medication errors in cancer clinical trials. In particular, understanding the nature and frequency of medication errors will assist in tailoring interventions to make patient care safer. 15, 16 The aim of this study was to investigate the effectiveness of pharmacist intervention in reducing and preventing prescribing errors of investigational drugs in cancer patients. In addition, we analyzed factors affecting prescribing errors.
Materials and methods

Study design and setting
A retrospective study was performed from December 2015 to February 2017 at the National Cancer Center, Korea. All orders of investigational drugs were eligible for this study. The exclusion criteria were as follows; correction of error by a prescriber without pharmacist intervention, change of order due to adverse events or poor conditions, cancellation of order due to withdrawal of consent, and cancellation of order due to progression of disease.
The cancer hospital where this study was conducted, provides care to approximately 1600 ambulatory patients and 500 inpatients per day. An electronic medical record (EMR) system, which includes a computerized order entry system, has been fully implemented since 2009. The investigational drug service (IDS) at the National Cancer Center Korea currently manages 180 clinical research studies. This study was approved by the Institutional Review Board of the National Cancer Center, Korea (IRB number: NCC2017-0087).
Pharmacist intervention
The evaluation was performed by the IDS pharmacists during two periods: a baseline period from December 2015 to June 2016 (before the active intervention by pharmacists) and an intervention period from July 2016 to February 2017. The completeness and error of orders in these two periods were compared.
Pharmacists performed active interventions, which included discussing prescribing method with investigators before the start of study and providing a prescribing guide via e-mail to the investigators and clinical research coordinators. The guide described the elements of a prescription that are required by law, as well as all information needed to dispense the drug according to study protocol. It also had common error types, precautions, a good order example (order sets), and information about the investigational drug.
Data collection and analysis
Investigational drug orders and pharmacist intervention records from December 2015 to February 2017 were collected from the EMR database. To review the prescribing order, a protocol-specific checklist was developed. The checklist included the protocol's name or number, the participant's identity (name, subject number or randomization number, and initial), the drug's identity (designation, drug name, dose, dosage form, and kit number), the drug quantity, the route of administration and diluent in intravenous (IV) medications, treatment duration or schedule, and investigator's name. Two IDS pharmacists reviewed the prescriptions independently using a protocol-specific checklist.
If IDS pharmacists detected problems (omissions or errors) in prescriptions, they communicated with the investigator by phone. Documents related to pharmacist prescription interventions were recorded in the EMR. This is the standard process for correcting prescriptions with errors at the National Cancer Center, regardless of study periods. A comparison was made of the two periods with regard to the rates and types of prescribing errors. Factors affecting prescribing errors were also analyzed.
Statistical analysis
Demographics of all data were expressed as frequency with percentage. A chi-square test was used to compare differences in distribution and prescribing error rates between the baseline group and the intervention group. Univariate and multivariate logistic regressions were carried out to investigate the significant factors affecting prescribing errors. Two-sided p values of <0.05 were considered to indicate statistical significance. Statistical analyses were performed using SPSS version 20.0 for windows (SPSS Inc., Chicago, IL, USA).
Results
A total of 12,779 orders of the investigational drug were prescribed during the study period. Among them, 392 orders were excluded due to correction of the error by the prescriber without a pharmacist intervention (n ¼ 314), change of order due to adverse events or poor condition (n ¼ 54), cancellation of order due to withdrawal of consent (n ¼ 16), and cancellation of order because of progression of the disease (n ¼ 8). Accordingly, data from 12,387 orders were used for the analysis.
As shown in Table 1 , there were 6477 orders in the baseline period and 5910 orders in the intervention period. There were significant differences in trial initiator (p < 0.01), participating site (p < 0.0001), study blindness (p < 0.0001), and clinical trial phase (p < 0.0001) between two periods.
Prescribing errors were classified, as described in Table 2 . Prescribing error rates decreased from 6.10% (395 errors out of 6477 orders) during the baseline period to 4.70% (278 errors out of 5910 orders) during the intervention period (difference 1.39; 95% CI: 0.60-2.19; p ¼ 0.0006). The most common prescribing error in both periods was wrong medication kit number (152 cases, 38.48% during the baseline period; 131 cases, 47.12% during the intervention). Wrong dose, wrong quantity, and wrong diluent were the next common errors.
As presented in Table 3 , pharmacist intervention, route of administration, study blindness, initiator, participating site, and clinical trial phase were significant factors for prescribing errors in the univariate analysis. Since there was strong association among initiator, participating site, and clinical trial phase, three models were conducted for the multivariate analysis. Model I included study blindness and participating site in addition to intervention and route of administration. Model II included initiator instead of participating site, as in model I. Model III included clinical trial phase instead of participating site, as in model I.
Pharmacist intervention reduced prescribing errors by at least 25% in all constructed models after adjusting for confounding variables. Prescribing errors occurred 1.3 times more frequently when the drug was IV than when it was oral. There were 60% fewer prescribing errors in the blinding study than in the open study. Sponsor initiated trial (SIT) and multi-center/ multi-nation study had 4.2 and 2.4 times higher prescribing error than investigator-initiated trial (IIT) and single center-single nation study, respectively. There were fewer errors in the phase 2 trial and trial covering both phase 1 and phase 2 (phase 1/2 trial) than in the phase 3 trial.
Discussion
In this study, prescribing error rates decreased from 6.10 % during the baseline period to 4.70 % with pharmacist intervention, meaning that IDS pharmacist intervention in cancer clinical trials improved medication safety and promoted adherence to protocol in a clinical trial. Several clinical studies have demonstrated that pharmacist intervention decreased prescribing errors by 4.1-17.7%. 17, 18 In particular, one study revealed that providing an educational and informative program to physicians by pharmacists improved prescription appropriateness by 4.5%. 19 The reduction of prescribing errors in this study is somewhat lower than in other pharmacist intervention studies. However the reduction in the prescribing error rate is meaningful, since prescribing errors in clinical trials can have a greater impact on patient safety and can lead to the success or failure of trials. A more stringent standard of error rates, close to zero, is needed. 20 The overall prescribing error rate in this study was 5.36%, which was higher than that in general anticancer drug studies. Prescribing error rates in general anticancer studies were reported to be 1.1-3%. 13, 14, 21, 22 The higher error rate was attributable to the fact that investigational drugs are more vulnerable to errors than commercial drugs due to protocol complexity, unfamiliarity with the study drug, and alphanumeric naming systems. 3 The frequency of prescribing error types was in the order of wrong medication kit number, wrong dose, and wrong quantity or wrong diluent. Unlike commercial drugs, investigational drugs have unique characteristics. Investigational drugs are often supplied with patientspecific supplies or individual kits to maintain blinding or to prevent dispensing errors. In such a case, a prescription error occurs due to the omission of kit numbers or wrong kit numbers. 23 Wrong kit numbers are usually caused by an error in a copy of the previous order or typing error.
Dose errors were commonly reported in other prescribing error studies. 10, [12] [13] [14] In oncology clinical trials, investigators may not be familiar with protocol-defined dose calculations or dose-rounding requirements.
Regarding the route of administration, the prescription error rate related to IV administration was higher than that of oral administration. IV therapy has a high risk of error due to its complexity. 24 Vijayakumar et al. showed that almost half of the patients (46.3%) administrated IV drugs demonstrated drug-related problems in clinical trials. 25 This is also related to the high frequency of wrong diluent (dilution solution and concentration).
SIT was the strongest factor affecting prescribing errors in this study (AOR: 4.16, 95% CI: 3.31-5.23). Most of the sponsors in SIT are pharmaceutical companies. In the case of clinical studies involving new drug substances, investigators are unfamiliar with dose, dosage form, and packaging units. As most SITs are conducted in a multi-national and multi-institutional way, sponsors write protocols in detail to reduce misunderstandings. Complex and detailed protocols have many components to consider in the course of prescribing medications. On the other hand, IIT is often used to study additional efficacy and safety of commercial drugs, so investigators are familiar with dose, dosage form, and packaging units. In addition, IIT does not use medication kit numbers, and the protocol is relatively simple compared to the SIT because the participating sites in the IIT are relatively few. 26 Unexpectedly, the prescription error rate in openlabel studies was higher than in blind studies. It was presumed that investigators are especially careful to prescribe, since blind study requires specialized procedures for performing patient randomization while maintaining blindness.
Compared to the phase 3 trial, phase 2 and phase 1/2 showed significantly decreased risk of prescribing error. Since phase 3 is more complex, due to the nature of large, long-term clinical trials that preferably perform in randomized double-blind design, [27] [28] [29] it seems that the risk of prescription error is less in phase 2 and other phases. There are some limitations in this study. It is a retrospective, single-center study. Another limitation is that it did not assess the severity of prescribing errors because there are no clear criteria for investigational drug use. Additionally, we could not find any harm induced by prescription errors. Since most prescription errors were detected by IDS pharmacists before the investigational drugs reached the patients, these errors did not result in patient harm.
However, to our knowledge, this is the first study that has evaluated the effects of IDS pharmacists' intervention on prescribing errors with investigational drugs in the CPOE system. In addition, by evaluating the types of the prescribing errors and by analyzing protocol designs, factors affecting prescribing errors were identified. These results will help us to improve the safety of investigational drug use in the future.
Conclusions
In conclusion, we have shown that pharmacist intervention in cancer clinical trials was associated with significant reductions in prescribing errors and may therefore lead to increased medication safety.
